HC Wainwright Expects Higher Earnings for Janux Therapeutics

Key Points

• HC Wainwright raised its Q1 2026 EPS estimate for Janux from ($0.63) to ($0.56), kept a Buy rating with a $45 price target, and projects losses through FY2029 before forecasting profitability in FY2030 (FY2026 EPS -$2.40 to FY2030 $1.08).
• Janux beat analysts' estimates for the quarter ended Feb. 26, reporting ($0.51) EPS versus a ($0.65) consensus and revenue of $7.88 million (vs. $0.08M expected), driving a roughly 6.8% intraday move higher.
• Insiders sold 19,033 shares totaling about $261,323 in the last quarter (including CEO sales), reducing insider ownership to 8.10%, while institutional investors own roughly 75% of the stock.

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Stock analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for Janux Therapeutics in a research note issued to investors on Monday, March 2nd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.56) for the quarter, up from their previous forecast of ($0.63). HC Wainwright currently has a "Buy" rating and a $45.00 target price on the stock. The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for Janux Therapeutics' Q2 2026 earnings at ($0.59) EPS, Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.64) EPS, FY2026 earnings at ($2.40) EPS, FY2027 earnings at ($2.97) EPS, FY2028 earnings at ($3.18) EPS, FY2029 earnings at ($1.01) EPS and FY2030 earnings at $1.08 EPS.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.14. The firm had revenue of $7.88 million during the quarter, compared to analyst estimates of $0.08 million.

JANX has been the topic of several other reports. Guggenheim dropped their target price on Janux Therapeutics from $72.00 to $68.00 and set a "buy" rating on the stock in a report on Friday, February 27th. Cantor Fitzgerald decreased their price target on Janux Therapeutics from $150.00 to $100.00 and set an "overweight" rating for the company in a research note on Friday, February 27th. Clear Str lowered shares of Janux Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, January 20th. Stifel Nicolaus dropped their price target on Janux Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research report on Tuesday, December 2nd. Finally, Bank of America cut their price objective on shares of Janux Therapeutics from $58.00 to $49.00 and set a "buy" rating on the stock in a research report on Tuesday, December 2nd. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $56.91.

Janux Therapeutics Stock Up 6.8%

Janux Therapeutics stock opened at $14.35 on Thursday. Janux Therapeutics has a 52-week low of $12.12 and a 52-week high of $35.34. The firm has a market capitalization of $872.91 million, a P/E ratio of -7.84 and a beta of 2.88. The firm has a fifty day moving average of $13.70 and a 200-day moving average of $20.47.

Insider Transactions at Janux Therapeutics

In related news, insider Zachariah Mciver sold 2,714 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $37,263.22. Following the completion of the sale, the insider directly owned 23,286 shares of the company's stock, valued at $319,716.78. This represents a 10.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David Alan Campbell sold 8,072 shares of Janux Therapeutics stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $110,828.56. Following the completion of the transaction, the chief executive officer owned 284,982 shares in the company, valued at $3,912,802.86. The trade was a 2.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 19,033 shares of company stock valued at $261,323 in the last quarter. 8.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Janux Therapeutics

Several hedge funds have recently modified their holdings of JANX. AQR Capital Management LLC increased its stake in Janux Therapeutics by 71.7% in the 1st quarter. AQR Capital Management LLC now owns 9,717 shares of the company's stock worth $262,000 after purchasing an additional 4,059 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Janux Therapeutics by 18.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,403 shares of the company's stock worth $583,000 after buying an additional 3,393 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Janux Therapeutics by 12.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 186,394 shares of the company's stock worth $5,033,000 after acquiring an additional 20,657 shares in the last quarter. Y Intercept Hong Kong Ltd raised its holdings in shares of Janux Therapeutics by 15.5% during the second quarter. Y Intercept Hong Kong Ltd now owns 20,602 shares of the company's stock valued at $476,000 after acquiring an additional 2,769 shares during the period. Finally, ProShare Advisors LLC raised its holdings in shares of Janux Therapeutics by 8.1% during the second quarter. ProShare Advisors LLC now owns 10,284 shares of the company's stock valued at $238,000 after acquiring an additional 771 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.